Veracyte Inc (VCYT) 7.40 $VCYT Veracyte Present
Post# of 273254
Posted On: 09/25/2016 5:07:51 AM
Veracyte Inc (VCYT) 7.40 $VCYT
Veracyte Presents Data Demonstrating Potential to Enhance Afirma® Gene Expression Classifier Using an RNA Sequencing Platform
PR Newswire - Fri Sep 23, 10:45AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced new data suggesting the potential to enhance the performance of the Afirma Gene Expression Classifier in thyroid cancer diagnosis by combining the test's proven RNA expression-based capabilities with gene variant and fusion information - all on a single, robust RNA sequencing platform. Such enhancements could help to further reduce the number of patients who undergo unnecessary surgery when their thyroid nodules are not clearly benign or cancerous (i.e., indeterminate) following routine cytopathology evaluation.
VCYT: 7.40 (+0.17)
Veracyte Secures Draft Medicare Local Coverage Determination for Percepta® Bronchial Genomic Classifier from Palmetto GBA
PR Newswire - Thu Sep 15, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), has posted a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. The Palmetto draft LCD posting follows the September 8 posting by Noridian Health Solutions, another participant in the MolDx Program that Palmetto GBA established and administers. The remaining two MolDx Program participating MACs are expected to similarly post the Percepta LCD in the future.
VCYT: 7.40 (+0.17)
Veracyte Announces Data from Seven Afirma® Gene Expression Classifier Studies to Be Presented at the 86th Annual Meeting of the American Thyroid Association
PR Newswire - Thu Sep 15, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that external researchers will present six posters that reinforce the role of the Afirma Gene Expression Classifier (GEC) as a new standard of care in thyroid cancer diagnosis at the 86th Annual Meeting of the American Thyroid Association (ATA), being held September 21-25 in Denver. Company scientists will also present data suggesting the potential to further enhance the Afirma GEC's performance by combining the test's proven RNA expression-based capabilities with gene variant and fusion information on a next-generation sequencing (NGS) platform.
VCYT: 7.40 (+0.17)
Veracyte Achieves Major Medicare Coverage Milestone for the Percepta® Classifier to Improve Lung Cancer Diagnosis
PR Newswire - Thu Sep 08, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Noridian Healthcare Solutions, the nation's largest Medicare Administrative Contractor (MAC), has issued a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. When finalized, this LCD will enable coverage for over 30 million - or more than half - of the Medicare beneficiaries in the United States. The Percepta classifier is the first genomic test for use in lung cancer diagnosis to achieve this important Medicare coverage milestone. The test is supported by multiple published studies demonstrating its ability to make lung cancer screening and diagnosis more accurate and safe by reducing unnecessary surgeries on suspicious lung nodules found on computed tomography (CT) scans.
VCYT: 7.40 (+0.17)
Veracyte to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 2:05 p.m. ET in New York City.
VCYT: 7.40 (+0.17), MS: 31.91 (-0.33)
Veracyte Announces Second Quarter 2016 Financial Results
PR Newswire - Wed Aug 03, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the second quarter ended June 30, 2016 and provided an update on recent business progress. For the second quarter of 2016, revenue was $14.7 million, an increase of 23%, compared to $11.9 million for the second quarter of 2015. Afirma Gene Expression Classifier (GEC) volume grew to 5,832 tests, an increase of 23%, compared to the same period in 2015. These results bring first-half 2016 revenue to $28.2 million and Afirma GEC volume to 11,184.
VCYT: 7.40 (+0.17)
Medical Instrument Aug 3 Earnings Lineup: TEAR, GI & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:46AM CDT
Here, we take a look at five Medical instrument stocks set to report their second-quarter 2016 numbers on Aug 3.
TEAR: 0.71 (unch), VCYT: 7.40 (+0.17), MASI: 59.77 (-0.55), ENTL: 20.30 (-0.30), GI: 4.12 (-0.05)
Veracyte Releases Statement on CMS's Final PAMA Rule
PR Newswire - Fri Jun 17, 5:51PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, issued the following statement in response to the Centers for Medicare and Medicaid Services' (CMS) release today of its final rule outlining how the agency will establish Medicare reimbursement rates for advanced genomic tests such as Veracyte's Afirma® Gene Expression Classifier (GEC) under the Protecting Access to Medicare Act (PAMA), beginning January 1, 2018.
VCYT: 7.40 (+0.17)
Veracyte Statement on CMS's Preliminary Gapfill Rate for the Afirma® Gene Expression Classifier
PR Newswire - Fri Jun 10, 8:45PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today issued the statement below on the Centers for Medicare and Medicaid Services' (CMS) preliminary "gapfill" Medicare reimbursement rate for Veracyte's Afirma Gene Expression Classifier (GEC), which the agency released this afternoon.
VCYT: 7.40 (+0.17)
Veracyte to Present at the William Blair & Company 36th Annual Growth Stock Conference
PR Newswire - Wed Jun 01, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Chris Hall, chief operating officer, will present at the William Blair & Company 36th Annual Growth Stock Conference on Wednesday, June 15th, 2016 at 2:40 p.m. CT in Chicago, IL.
VCYT: 7.40 (+0.17)
Veracyte Announces New Data that Advance Understanding of the Role of Gene Alterations In Thyroid Cancer Diagnosis
PR Newswire - Fri May 27, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced findings from two studies demonstrating the challenge of using large gene-mutation panels to help physicians determine next steps for patients whose thyroid nodules are not clearly benign or malignant following routine cytopathology evaluation. Company researchers also unveiled a new study designed to identify RNA-based gene alteration and other data that may be useful in guiding physician decision-making for thyroid nodule patients. The studies are being presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress, taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 7.40 (+0.17)
Veracyte Announces Data from Multiple Studies Advancing Scientific Understanding of Thyroid Cancer to Be Presented at AACE Congress
PR Newswire - Mon May 23, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that company scientists and external researchers will present new data advancing the science around the role of gene alterations and transcriptions in thyroid cancer diagnosis at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 7.40 (+0.17)
New Data Demonstrating Ability of Veracyte's Genomic Test to Improve Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2016
PR Newswire - Tue May 17, 4:30PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced findings from a new study demonstrating the potential for the company's in-development Envisia classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILD) without the need for invasive and potentially risky surgery. Additional data from three other studies suggest the potential for the test to address several challenges that currently hinder accurate and timely diagnosis of the disease. The findings were presented at the American Thoracic Society (ATS) 2016 International Conference taking place May 13-18 in San Francisco.
VCYT: 7.40 (+0.17)
Veracyte reports 1Q loss
Automated Insights - Thu May 05, 4:15PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a loss of $10.1 million in its first quarter.
VCYT: 7.40 (+0.17)
Veracyte Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on recent business progress. For the first quarter of 2016, revenue was $13.6 million, an increase of 21%, compared to $11.2 million for the first quarter of 2015. Afirma Gene Expression Classifier (GEC) test volume grew to 5,352 tests, an increase of 33%, compared to the same period in 2015.
VCYT: 7.40 (+0.17)
/C O R R E C T I O N -- Veracyte/
PR Newswire - Tue Apr 19, 11:01AM CDT
In the news release, Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on Thursday, May 5, 2016, issued 19-Apr-2016 by Veracyte over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2016 financial results after close of market on Thursday, May 5, 2016" rather than "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2015 financial results after close of market on Thursday, May 5, 2016" as originally issued inadvertently. The complete, corrected release follows:
VCYT: 7.40 (+0.17)
Veracyte Receives Regulatory Authorization to Offer Percepta(TM) Bronchial Genomic Classifier for Patients in New York State
PR Newswire - Thu Jan 28, 6:30AM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has received regulatory authorization from the New York State Department of Health to offer the Percepta(TM) Bronchial Genomic Classifier for patients in the state. The genomic test, commercially introduced in April 2015, is used to help patients avoid unnecessary invasive, risky and costly procedures to assess potentially cancerous lung nodules that were initially found on CT scans.
VCYT: 7.40 (+0.17)
Veracyte to Participate in Two Upcoming Investor Conferences
PR Newswire - Wed Jan 27, 7:00AM CST
Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th 2016 at 11:05 a.m. ET in New York, NY.
VCYT: 7.40 (+0.17)
Veracyte Presents Data Demonstrating Potential to Enhance Afirma® Gene Expression Classifier Using an RNA Sequencing Platform
PR Newswire - Fri Sep 23, 10:45AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced new data suggesting the potential to enhance the performance of the Afirma Gene Expression Classifier in thyroid cancer diagnosis by combining the test's proven RNA expression-based capabilities with gene variant and fusion information - all on a single, robust RNA sequencing platform. Such enhancements could help to further reduce the number of patients who undergo unnecessary surgery when their thyroid nodules are not clearly benign or cancerous (i.e., indeterminate) following routine cytopathology evaluation.
VCYT: 7.40 (+0.17)
Veracyte Secures Draft Medicare Local Coverage Determination for Percepta® Bronchial Genomic Classifier from Palmetto GBA
PR Newswire - Thu Sep 15, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), has posted a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. The Palmetto draft LCD posting follows the September 8 posting by Noridian Health Solutions, another participant in the MolDx Program that Palmetto GBA established and administers. The remaining two MolDx Program participating MACs are expected to similarly post the Percepta LCD in the future.
VCYT: 7.40 (+0.17)
Veracyte Announces Data from Seven Afirma® Gene Expression Classifier Studies to Be Presented at the 86th Annual Meeting of the American Thyroid Association
PR Newswire - Thu Sep 15, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that external researchers will present six posters that reinforce the role of the Afirma Gene Expression Classifier (GEC) as a new standard of care in thyroid cancer diagnosis at the 86th Annual Meeting of the American Thyroid Association (ATA), being held September 21-25 in Denver. Company scientists will also present data suggesting the potential to further enhance the Afirma GEC's performance by combining the test's proven RNA expression-based capabilities with gene variant and fusion information on a next-generation sequencing (NGS) platform.
VCYT: 7.40 (+0.17)
Veracyte Achieves Major Medicare Coverage Milestone for the Percepta® Classifier to Improve Lung Cancer Diagnosis
PR Newswire - Thu Sep 08, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Noridian Healthcare Solutions, the nation's largest Medicare Administrative Contractor (MAC), has issued a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. When finalized, this LCD will enable coverage for over 30 million - or more than half - of the Medicare beneficiaries in the United States. The Percepta classifier is the first genomic test for use in lung cancer diagnosis to achieve this important Medicare coverage milestone. The test is supported by multiple published studies demonstrating its ability to make lung cancer screening and diagnosis more accurate and safe by reducing unnecessary surgeries on suspicious lung nodules found on computed tomography (CT) scans.
VCYT: 7.40 (+0.17)
Veracyte to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 2:05 p.m. ET in New York City.
VCYT: 7.40 (+0.17), MS: 31.91 (-0.33)
Veracyte Announces Second Quarter 2016 Financial Results
PR Newswire - Wed Aug 03, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the second quarter ended June 30, 2016 and provided an update on recent business progress. For the second quarter of 2016, revenue was $14.7 million, an increase of 23%, compared to $11.9 million for the second quarter of 2015. Afirma Gene Expression Classifier (GEC) volume grew to 5,832 tests, an increase of 23%, compared to the same period in 2015. These results bring first-half 2016 revenue to $28.2 million and Afirma GEC volume to 11,184.
VCYT: 7.40 (+0.17)
Medical Instrument Aug 3 Earnings Lineup: TEAR, GI & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:46AM CDT
Here, we take a look at five Medical instrument stocks set to report their second-quarter 2016 numbers on Aug 3.
TEAR: 0.71 (unch), VCYT: 7.40 (+0.17), MASI: 59.77 (-0.55), ENTL: 20.30 (-0.30), GI: 4.12 (-0.05)
Veracyte Releases Statement on CMS's Final PAMA Rule
PR Newswire - Fri Jun 17, 5:51PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, issued the following statement in response to the Centers for Medicare and Medicaid Services' (CMS) release today of its final rule outlining how the agency will establish Medicare reimbursement rates for advanced genomic tests such as Veracyte's Afirma® Gene Expression Classifier (GEC) under the Protecting Access to Medicare Act (PAMA), beginning January 1, 2018.
VCYT: 7.40 (+0.17)
Veracyte Statement on CMS's Preliminary Gapfill Rate for the Afirma® Gene Expression Classifier
PR Newswire - Fri Jun 10, 8:45PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today issued the statement below on the Centers for Medicare and Medicaid Services' (CMS) preliminary "gapfill" Medicare reimbursement rate for Veracyte's Afirma Gene Expression Classifier (GEC), which the agency released this afternoon.
VCYT: 7.40 (+0.17)
Veracyte to Present at the William Blair & Company 36th Annual Growth Stock Conference
PR Newswire - Wed Jun 01, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Chris Hall, chief operating officer, will present at the William Blair & Company 36th Annual Growth Stock Conference on Wednesday, June 15th, 2016 at 2:40 p.m. CT in Chicago, IL.
VCYT: 7.40 (+0.17)
Veracyte Announces New Data that Advance Understanding of the Role of Gene Alterations In Thyroid Cancer Diagnosis
PR Newswire - Fri May 27, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced findings from two studies demonstrating the challenge of using large gene-mutation panels to help physicians determine next steps for patients whose thyroid nodules are not clearly benign or malignant following routine cytopathology evaluation. Company researchers also unveiled a new study designed to identify RNA-based gene alteration and other data that may be useful in guiding physician decision-making for thyroid nodule patients. The studies are being presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress, taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 7.40 (+0.17)
Veracyte Announces Data from Multiple Studies Advancing Scientific Understanding of Thyroid Cancer to Be Presented at AACE Congress
PR Newswire - Mon May 23, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that company scientists and external researchers will present new data advancing the science around the role of gene alterations and transcriptions in thyroid cancer diagnosis at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 7.40 (+0.17)
New Data Demonstrating Ability of Veracyte's Genomic Test to Improve Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2016
PR Newswire - Tue May 17, 4:30PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced findings from a new study demonstrating the potential for the company's in-development Envisia classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILD) without the need for invasive and potentially risky surgery. Additional data from three other studies suggest the potential for the test to address several challenges that currently hinder accurate and timely diagnosis of the disease. The findings were presented at the American Thoracic Society (ATS) 2016 International Conference taking place May 13-18 in San Francisco.
VCYT: 7.40 (+0.17)
Veracyte reports 1Q loss
Automated Insights - Thu May 05, 4:15PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a loss of $10.1 million in its first quarter.
VCYT: 7.40 (+0.17)
Veracyte Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on recent business progress. For the first quarter of 2016, revenue was $13.6 million, an increase of 21%, compared to $11.2 million for the first quarter of 2015. Afirma Gene Expression Classifier (GEC) test volume grew to 5,352 tests, an increase of 33%, compared to the same period in 2015.
VCYT: 7.40 (+0.17)
/C O R R E C T I O N -- Veracyte/
PR Newswire - Tue Apr 19, 11:01AM CDT
In the news release, Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on Thursday, May 5, 2016, issued 19-Apr-2016 by Veracyte over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2016 financial results after close of market on Thursday, May 5, 2016" rather than "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2015 financial results after close of market on Thursday, May 5, 2016" as originally issued inadvertently. The complete, corrected release follows:
VCYT: 7.40 (+0.17)
Veracyte Receives Regulatory Authorization to Offer Percepta(TM) Bronchial Genomic Classifier for Patients in New York State
PR Newswire - Thu Jan 28, 6:30AM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has received regulatory authorization from the New York State Department of Health to offer the Percepta(TM) Bronchial Genomic Classifier for patients in the state. The genomic test, commercially introduced in April 2015, is used to help patients avoid unnecessary invasive, risky and costly procedures to assess potentially cancerous lung nodules that were initially found on CT scans.
VCYT: 7.40 (+0.17)
Veracyte to Participate in Two Upcoming Investor Conferences
PR Newswire - Wed Jan 27, 7:00AM CST
Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th 2016 at 11:05 a.m. ET in New York, NY.
VCYT: 7.40 (+0.17)
(0)
(0)Scroll down for more posts ▼